Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03609437
Other study ID # esus-endothelium-attikon
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date June 30, 2018

Study information

Verified date July 2018
Source University of Athens
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cardioembolism is a postulated mechanism of an embolic stroke of undetermined source (ESUS). The investigators will measure endothelial glycocalyx, aortic elastic properties, oxidative stress, and their association with left ventricular (LV) and left atrial (LA) function in ESUS and age- and sex-adjusted healthy individuals.


Description:

The investigators aim to evaluate consecutive acute ischemic stroke (AIS) patients satisfying ESUS diagnostic criteria in a single tertiary care stroke center (University Hospital, Athens, Greece). Moreover, baseline characteristics and outcome measures for all AIS patients are going to be recorded and further be classified, according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) and ESUS criteria. Healthy volunteers (colleagues, friends, relatives and others) will be included in the control group.

In participants (patients and controls) the investigators plan to measure: a) perfused boundary region (PBR) of the sublingual arterial microvessels (range 5-25 micrometers), a marker inversely related with glycocalyx thickness, b) pulse wave velocity (PWV), central systolic blood pressure (cSBP) and augmentation index (AIx), c) LV Global Longitudinal strain (GLS), d) LA volume and strain using speckle-tracking strain imaging, e) Malondialdehyde (MDA), as an oxidative stress marker.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date June 30, 2018
Est. primary completion date June 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

The clinical entity of ESUS is defined according to the criteria proposed by the Cryptogenic Stroke/ESUS International Working Group:

(1) stroke visualized by computed tomography (CT) or magnetic resonance imaging (MRI) that is not lacunar (Lacunar defined as a subcortical infarct 1.5 cm or 2.0 cm on MRI diffusion images in largest dimension), (2) absence of extra-cranial or intra-cranial atherosclerosis causing >50% luminal stenosis or occlusion of arteries supplying the area of ischemia (Requires extra-cranial and intra-cranial arterial imaging using sonography, computed tomography angiography, or magnetic resonance angiography of the relevant arteries) (3) no major-risk cardioembolic source of embolism by history, electrocardiography, echocardiography and >24 h of cardiac rhythm monitoring [Permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intra-cardiac thrombus, mechanical prosthetic cardiac valve, atrial myxoma or other cardiac tumors, moderate/severe mitral stenosis, recent (<4 weeks) myocardial infarction, valvular vegetations, or infective endocarditis] (4) no other specific cause of ischemic stroke identified (e.g. arteritis, dissection, migraine/vasospasm, drug abuse)

Exclusion Criteria

1. factors associated with a medium or high risk for thrombus formation in patients with stroke, such as the presence of aortic or mitral valvular prostheses, history of atrial fibrillation (AF) or atrial flutter, known or suspected cardiomyopathy, infective endocarditis, atrial septal defect and intracardiac tumor or thrombus

2. potential confounders in the measurement of left atrial (LA) mechanical function, including the presence of significant (>50% luminal) coronary artery stenosis, previous myocardial infarction or regional wall motion abnormality, prior administration of cardiotoxic chemotherapeutic agents, sick sinus syndrome, any valvular lesion of >2+ severity and pregnancy.

These exclusion criteria are applied to both patients and control subjects.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Greece Konstantinos Katogiannis Athens Attiki

Sponsors (1)

Lead Sponsor Collaborator
University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of endothelial glycocalyx thickness between patients with embolic stroke of undetermined source (ESUS) and controls Investigators will assess endothelial glycocalyx thickness by evaluating perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels (range 5-25 micrometers) for patients with embolic stroke of undetermined source (ESUS) and controls. Baseline
Secondary Comparison of arterial stiffness between patients with embolic stroke of undetermined source (ESUS) and controls. Investigators aim to evaluate arterial stiffness by pulse wave velocity (PWV,m/sec) using tonometry in patients with embolic stroke of undetermined source (ESUS) and controls. Baseline
Secondary Assessment of left ventricular global longitudinal strain (GLS, %) in patients with embolic stroke of undetermined source (ESUS) and controls. Investigators plan to assess left ventricular in patients with embolic stroke of undetermined source (ESUS) and controls. Baseline
Secondary Serum malondialdehyde levels in patients with embolic stroke of undetermined source (ESUS) and controls. Investigators plan to compare serum malondialdehyde levels in patients with embolic stroke of undetermined source (ESUS) and controls. Baseline
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT04156711 - Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2
Completed NCT05872139 - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging N/A
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02334839 - The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction N/A
Recruiting NCT02020044 - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Completed NCT01691404 - Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO) N/A
Terminated NCT01412216 - The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance Phase 2
Completed NCT01319344 - Effect of Eplerenone on Endothelial Function in Metabolic Syndrome Phase 3
Completed NCT00987974 - Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury Phase 4
Completed NCT00990730 - Atherosclerosis in Rheumatoid Arthritis N/A
Completed NCT00848302 - Endothelial Function in Human Arteries Early Phase 1
Completed NCT00532844 - A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction Phase 2
Completed NCT00376246 - Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects Phase 4
Completed NCT00775099 - Combustion Derived Air Pollution and Vascular Function N/A